Related references
Note: Only part of the references are listed.Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
A. Craig Lockhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models
Xiaoyu Yan et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2010)
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
Quincy Siu-Chung Chu
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer
C. N. Sternberg
ANNALS OF ONCOLOGY (2008)
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters
Julie Bertrand et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2008)
Approximations of the target-mediated drug disposition model and identifiability of model parameters
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
C. Kut et al.
BRITISH JOURNAL OF CANCER (2007)
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
Naoto Hayashi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model:: Application to HIV dynamics model
Adeline Samson et al.
COMPUTATIONAL STATISTICS & DATA ANALYSIS (2006)
A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis
Sofia Baka et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2006)
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide
Karl Brendel et al.
PHARMACEUTICAL RESEARCH (2006)
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
PHARMACEUTICAL RESEARCH (2005)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans
SM Eppler et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Share Paper
